2nd mRNA Analytical Development Summit Europe

With continued pressure on drug development timelines paired with a lack of regulatory guidance, the demand for innovative, efficient, and high-throughput analytical methods is crucial to ensure the approval and successful commercialisation of safe and effective mRNA therapeutics and vaccines.

As such, the highly anticipated 2nd mRNA Analytical Development Summit Europe 2024 returns to Berlin as the premier gathering for industry professionals to delve into optimised mRNA analytics. Join us to gain critical expertise and hear the latest techniques adopted by Europe's leading biopharma leaders.

Reuniting 80+ industry experts in Analytical Development, Quality Control, Quality Assurance, CMC, and Regulatory, this forum aims to tackle pivotal challenges within mRNA analytical development including biophysical characterisation, dsRNA, and tail sequence analysis. We will also tackle issues related to analytical techniques to meet CQAs and CPIs for efficient and expeditious approval, as well as hurdles related to improved stability and effective delivery systems for large-scale productions to improve tissue-specific delivery.

Across this comprehensive 3-day forum, we foster a collaborative community of like-minded experts from across Europe. Prepare to engage in dynamic discussions, gain invaluable insights, and forge meaningful connections that propel the field of mRNA therapeutics and vaccines forward.

Prices:
Conference + 2 Workshops - Academic Pricing: EUR 3197.00,
Conference + 2 Workshops - Industry Pricing: EUR 3797.00,
Conference + 2 Workshops - Service and Solution Provider Pricing: EUR 4597.00,
Conference + 1 Workshop - Academic Pricing: EUR 2798.00,
Conference + 1 Workshop - Industry Pricing: EUR 3298.00,
Conference + 1 Workshop - Service and Solution Provider Pricing: EUR 4198.00,
Conference Only - Academic Pricing: EUR 2399.00,
Conference Only - Industry Pricing: EUR 2799.00,
Conference Only - Service and Solution Provider Pricing: EUR 3599.00

Speakers: Aditi Mehta, Head of mRNA Process and Delivery, Merck, Ajit Magadum, Associate Scientist, Temple University College of Science and Technology, Erik Dreaden, Director, Delivery Science and Development, Moderna, Heinrich Haas, Chief Technology Officer, NeoVac, Ioannis Giannios, Project Manager, Sensible Therapeutics, Iulia Oita, Chemistry, Manufacturing and Controls Manager, Ziphius Vaccines NV, James Shu, Vice President - Analytical Science, Abogen Biosciences, Jitendra Kumar, Lead Chemistry, Entos Pharmaceuticals, Marco Morani, mRNA Analytical Development and Characterisation, Scientist Sanofi, Meryem Chennan, Senior Manager Regulatory Affairs CMC, CureVacSE, Philippe Le Mignot, Associate Director Electrophoresis, GlaxoSmithKline , Philippe Talaga, Global Head of Research Platforms, CMC Leaders and Experts, Sanofi, Robert Place, Senior Vice President - Innovation, MiNA Therapeutics, Tom Mulroney, Postdoctoral Research Associate, University of Cambridge, Tomasz Witkos, Associate Director, CMC Analytical Development, AstraZeneca, Yi Kuang, Assistant Professor, Hong Kong Science and Technology Parks, Yurong Guo, Senior Director - Analytical Development, Arcturus Therapeutics, Zoltán Kis, Senior Lecturer (Associate Professor), University of Sheffield

Others Details

URL:
Brochure: https://go.evvnt.com/2403343-3?pid=6581 

Category: Conferences | Health